We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -6.50 | -1.11% | 576.50 | 2,473,365 | 16:35:17 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 575.50 | 578.00 | 602.00 | 558.00 | 581.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 1.09B | USD 2M | USD 0.0152 | 380.26 | 766.41M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:48:18 | O | 166,296 | 576.4025 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/10/2024 | 19:30 | ALNC |  TOP NEWS: Shares in Indivior plunge 19% as profit warning |
| 10/10/2024 | 12:00 | UK RNS | Indivior PLC Preliminary Q3 Results & Updated FY 2024 Guidance |
| 08/10/2024 | 07:00 | UK RNS | Indivior PLC Transaction in Own Shares |
| 04/10/2024 | 11:33 | ALNC | IN BRIEF: Indivior Chair Graham Hetherington to retire at year-end |
| 03/10/2024 | 14:30 | UK RNS | Indivior PLC Chair Succession Plan |
| 01/10/2024 | 07:58 | UK RNS | Indivior PLC Total Voting Rights |
| 01/10/2024 | 07:00 | UK RNS | Indivior PLC Transaction in Own Shares |
| 24/9/2024 | 07:00 | UK RNS | Indivior PLC Transaction in Own Shares |
| 17/9/2024 | 07:00 | UK RNS | Indivior PLC Transaction in Own Shares |
| 12/9/2024 | 07:00 | UK RNS | Indivior PLC Holding(s) in Company |
Indivior (INDV) Share Charts1 Year Indivior Chart |
|
1 Month Indivior Chart |
Intraday Indivior Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/10/2024 | 15:22 | INDIVIOR THE PILL WITH NO CHEERS OR BEERS | 4,186 |
| 09/3/2020 | 10:34 | RB. de-merger | 548 |
| 11/7/2019 | 08:29 | Johnson & Johnson court case oklahoma | 6 |
| 03/5/2019 | 10:16 | Judgement against insys | 2 |
| 31/7/2018 | 13:45 | Indivior (INDV) IP Battle Status | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 13/10/2024 09:20 by Indivior Daily Update Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 583p.Indivior currently has 131,459,324 shares in issue. The market capitalisation of Indivior is £759,834,893. Indivior has a price to earnings ratio (PE ratio) of 380.26. This morning INDV shares opened at 581.50p |
Posted at 10/10/2024 18:49 by waldron Benjamin ChiouSharecast News 10 Oct, 2024 17:01 Europe close: Stocks inch lower after choppy session Thursday saw choppy trading across European stock markets with the region's main benchmark finishing lower but moving within a narrow range, as investors focused on mixed economic data from the US and developments in the Middle East. The Stoxx 600 index closed down 0.18% (0.94 points) at 519.11, with less than four points separating the intraday high (521.08) and low (517.81). Wall Street stocks got off to a weak start after inflation and jobless claims data blurred the outlook for the next Federal Reserve policy decision. Following last week's bumper payroll report, markets had begun to lower their expectations for another big rate cut from the Fed. But data out on Thursday showed that jobless claims had jumped to their highest since June 2023, reviving hopes that more policy action could be on the cards to ease the strain on the economy. Nevertheless, figures showed that the annual rate of US consumer price inflation slowed to a three-and-a-half-yea Meanwhile, oil prices were once again on the rise as tensions in the Middle East continued to escalate. Brent was up 2.1% at $78.19 a barrel by the close in Europe, after having pulled back sharply over recent days since topping the $80 mark on Monday. “It looks increasingly likely that Israel will go for a large-scale attack on Iran, as reports emerge of Gulf states lobbying the US to rein in its ally," said Chris Beauchamp, chief market analyst at IG. "Oil prices have surged on hints that Israel is seeking to take advantage of the Iranian attack to deliver a major strike on its opponent. The consequences of that could include a closing of the Straits of Hormuz, leading to major disruption to oil supplies.” Back in Europe, data showed that retail sales in Germany rose over the past two months. According to delayed data from the Federal Statistical Office, sales volumes increased by 1.6% during August, following a 1.5% gain in July and a 1.1% decline in June. Destatis released figures for the past three months in one go on Thursday after suspending a number of key economic indicators in May due to a failed IT systems update at the Wiesbaden-based authority. Market movers GSK was among the best performers on the Stoxx 600, rising 3% after the London-listed pharma giant agreed to settle about 93% of US cases in its Zantac lawsuits for up to $2.2bn. The settlement figure was close to the "best case scenario", according to Jefferies, which said the announcement should remove a significant weight on the share price. Deutsche Telekom rose 2% on plans to lift its dividend and buy back shares on the back of better revenue expectations in the next three years. Leading the fallers was UK pharma firm Indivior after delivering its second profit warning this year. Shares were down 19% after Indivior said it was seeing faster initial adoption among treatment providers of a competing long-acting injectable to its Sublocade treatment, as it cut its full-year sales and earnings targets |
Posted at 10/8/2024 06:59 by misca2 Indivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action LawsuitAugust 09, 2024 at 09:54 pm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Indivior PLC (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024. Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders (“OUD”) and serious mental illnesses. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Invidior PLC (INDV) Misled Investors Regarding the Financial Prospects of its Products According to the complaint, during the class period, defendants: (i) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than Defendants had led investors and analysts to believe; (ii) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company’s anticipated revenue and other financial metrics; (iii) knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY2024 net revenue guidance, including FY2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; and (iv) knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS. On July 9, 2024, Indivior issued a press release "announc[ing] a business update encompassing [its] outlook for [second quarter (‘Q2’)] and FY2024 financial performance." The July 9 Update reduced FY 2024 (i) total net revenue guidance to $1.15-$1.215 billion from the previous ranges of $1.24-$1.33 billion; (ii) SUBLOCADE net revenue guidance to $765-$805 million from the previous range of $820-$880 million; and (iii) OPVEE net revenue guidance to $9-14 million from the previous range of $15-25 million. The July 9 Update also shockingly advised that the Company would immediately cease all sales and marketing activities related to PERSERIS. On this news, Indivior's stock price fell $5.15 per share, or 33.57%, to close at $10.19 per share. What Now: You may be eligible to participate in the class action against Invidior PLC. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by October 1, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Invidior PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. View source version on businesswire.com: |
Posted at 06/8/2024 07:15 by adrian j boris INDIVIOR PLC (THE 'COMPANY')Completion of Share Repurchase Program August 6, 2024 Indivior PLC announces that the share repurchase program announced on November 17, 2023 to repurchase its ordinary shares of $0.50 each (the "Shares") for cancellation has now completed. In aggregate, Morgan Stanley & Co. International Plc, who undertook the program on the Company's behalf, purchased 5,944,547 Shares for a total consideration of $99,985,139.07 at an average price of £13.2821 per Share. Following completion of the above program, the Company has now commenced the share repurchase program announced on July 25, 2024 under which it will purchase Shares for up to a maximum consideration of $100m during the period commencing on the business day following the completion of the above program and ending no later than January 31, 2025. |
Posted at 25/7/2024 07:36 by hunter154 Funny how the $160m provision wasn't mentioned 2 weeks ago.Apart from that, nothing new. Accelerated buy backs should put a floor on the Share Price |
Posted at 17/7/2024 10:53 by davius Just been giving Indivior a cursory look...Market cap £1bn, bottom end of expected profit £220m, P/E under 5. $100m a year on share buy backs. A poorly received update. I'm missing something significant. Otherwise the share price fall looks well over done. |
Posted at 17/7/2024 08:42 by imjustdandy Overdone now. Gradual recovery of the share price |
Posted at 09/7/2024 13:26 by dealy on the subject of buybacks, the CEO said, "Given the share price" they will "actively assess" the use of cash (which seems to imply they will allocate more cash to buy backs) |
Posted at 09/7/2024 08:53 by ricky46 So on the 23/5 they reconfirm guidance, that was so they got the Nasdaq listing away as smooth as possible, then the share price drifts on a leaky ship, then 7 weeks later they drop all this news, terrible untrustworthy management in my opinion glad I sold out on the drift down, wish everyone the best of luck |
Posted at 04/7/2024 08:35 by swinsco "Indivior CEO Expects Ongoing U.S. Opioid Crisis to Drive Sales Growth"WSJ business news article out after hours yesterday. It's behind a paywall but the headline gives the right impression. Nasdaq share price recovered and finished flat yesterday which is showing up in today's opening price. |
Posted at 12/3/2022 17:05 by typo56 The news is quite possibly a continuation of this from 23 Feb.."Indivior, the FTSE 250-listed opiod addiction treatment company, is rumoured to be the mystery bidder circling Opiant Pharmaceuticals, the US-listed developer of medicines for drug addiction. People following the situation have heard rumours Indivior has been talking to Opiant since December last year year about a possible offer for the company." Good or bad for the INDV share price? You decide! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
